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NO-donating compounds for glaucoma. In particular, latano-
prostene bunod (VESNEO; Bausch and Lomb), a modified 
version of the existing glaucoma drug latanoprost, contains 
an NO-donating moiety and is modestly effective at reducing 
elevated IOP by ≈1.5 mmHg over latanoprost alone in ocular 
hypertensive patients.[11–13] Despite the promise of NO as a 
glaucoma therapy, significant challenges remain before the full 
IOP-reducing potential of NO can be realized.
NO plays a multifaceted role within the conventional outflow 
pathway such that its therapeutic effect depends strongly upon 
the location and concentration of NO delivered.[14] Some effects 
of NO may also be counterproductive and tend to cause IOP 
elevation that opposes the desired therapeutic outcome. For 
instance, NO delivery to the smooth muscle cells of the ciliary 
muscle (CM) causes CM relaxation.[15] As CM tension main-
tains patency of the conventional outflow pathway, NO-induced 
relaxation of the CM increases outflow resistance and elevates 
IOP.[15–17] Acting as a vasodilator, NO may also increase IOP 
by increasing downstream episcleral venous pressure[18] or by 
altering choroidal blood volume.[19] Dosing is also important, 
as high levels of NO can exacerbate off-target effects.[20] Fur-
thermore, the reactive nature of NO and its short half-life only 
allows NO to diffuse over short distances,[21,22] which severely 
limits the efficacy of topical drug preparations from reaching 
deep into the outflow pathway where resistance is generated. 
In order to fully exploit the IOP-reducing potential of NO, it is 
therefore necessary to achieve local and controlled delivery of 
NO deep in the conventional outflow pathway. To our knowl-
edge, NO-mediated IOP-lowering therapeutics that primarily 
target the conventional outflow pathway do not currently exist.
Here, we develop and test an NO delivery platform that 
directly targets the conventional outflow pathway and locally 
liberates a controlled dose of NO via enzyme biocatalysis 
(Scheme 1a). In our approach, enzymes are embedded at the 
desired sites and serve as biological machinery that can locally 
convert externally administered NO donors into active thera-
peutics. To enmesh enzymes deep within the TM, which is 
the principal resistance-generating region, we encapsulate 
β-galactosidase in polymer carriers. We fabricate polymer carrier 
capsules via layer-by-layer adsorption of interacting polymers 
onto sacrificial particle templates,[23–28] a versatile technique 
that allows incorporation of an extensive choice of materials 
within the multilayer structures and gives fine control over the 
diffusion of molecules across the shell of the polymer capsules. 
In this study, we chose hydrogen-bonded polymer pairs based 
Glaucoma is the second leading cause of irreversible blindness 
that affects more than 60 million people worldwide. Elevated 
intraocular pressure (IOP) is the primary risk factor,[1,2] and 
reducing IOP is the only clinical approach to prevent further 
glaucomatous vision loss.[3,4] All daily therapies, however, fail 
to achieve sufficient IOP reduction, likely because they do not 
target the conventional outflow pathway that controls IOP and 
becomes diseased in glaucoma.[2] The conventional outflow 
pathway is the primary route of aqueous humor outflow from 
the eye, and increased resistance deep in this pathway, where 
the trabecular meshwork (TM) and Schlemm’s canal (SC) inner 
wall interact, causes IOP elevation in glaucoma. Nitric oxide 
(NO), a key signaling molecule responsible for mediating a 
wide array of physiological roles across multiple biological sys-
tems, decreases outflow resistance and lowers IOP in various 
animal models and human patients.[5–13] Due to the therapeutic 
potential of NO, many efforts have focused on developing 
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on thiol-functionalized poly(methacrylic acid) (PMASH) and 
poly(N-vinylpyrrolidone) (PVP) as the system to encapsulate 
enzyme β-galactosidase (Scheme 1b) due to their high colloidal 
stability, (bio)degradability, and biocompatibility.[29–31] These 
capsules have previously been used to encapsulate a range of 
functional and active biomolecules, including enzymes,[32–34] 
DNA,[35,36] anticancer drugs,[37,38] antigenic peptides,[30,39] and 
intact proteins.[31,40] Successful delivery of vaccines using PMA 
carriers have been demonstrated in vivo.[31] We encapsulate NO 
donor, β-gal-NONOate, in liposomes because these lipid nanocar-
riers allow for sustained release of biomolecules and their proper-
ties can be modulated through the judicious choice of the lipid 
composition.[41–43] Liposomes have been used to encapsulate latan-
oprost[44] and plasmid DNA,[45] and injected into eyes in vivo. In 
our study, liposomes are delivered to the outflow pathway. Upon 
degradation of the lipid vesicles, NO donors are slowly released to 
the TM, where the enzyme is enmeshed, and enzymatic activity 
of β-galactosidase results in local delivery of active therapeutic 
NO at the outflow resistance sites, thus achieving an on-site NO 
delivery to the conventional outflow pathway.
In the current study, we: i) assemble β-galactosidase-loaded 
polymer capsules and β-gal-NONOate-loaded liposomes, 
ii) demonstrate local release of NO via biocatalysis of β-gal-
NONOate by β-galactosidase and investigate the reaction 
kinetics in vitro, iii) demonstrate control over the dose and time 
of NO release via an enzyme-prodrug mechanism, and iv) dem-
onstrate the effect of localized delivery of NO to the conven-
tional outflow pathway on outflow resistance in mouse models. 
Here, we present direct evidence that on-site delivery of NO 
to the outflow resistance sites provides efficacious therapeutic 
alteration of aqueous humor dynamics.
We first investigated NO release kinetics achieved via catalytic 
activity of β-galactosidase on β-gal-NONOate in mock aqueous 
humor solution (DBG solution: Dulbecco’s phosphate buffered 
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Scheme 1. a) Schematic illustration of localized delivery of nitric oxide (NO) to the conventional outflow pathway via enzyme biocatalysis. Left: Ante-
rior segment of eye showing the direction of aqueous humor flow in blue. Center: Enlargement of the iridocorneal angle (boxed region in left panel) 
showing the conventional outflow pathway. Right: Schematic of localized NO delivery within the trabecular meshwork (TM) near Schlemm’s canal 
(SC). β-Galactosidase is encapsulated in poly(methacrylic acid) (PMA) capsules and enmeshed within the TM. Liposomes containing NO donors 
(β-gal-NONOate) are delivered to the outflow pathway. Upon liposome degradation, NO donors are slowly released at the outflow resistance sites and 
enzymatic activity of β-galactosidase results in local delivery of active therapeutic NO at the outflow resistance sites, achieving a targeted on-site NO 
delivery to the conventional outflow pathway. CC: collector channels, CM: ciliary muscle, JCT: juxtacanalicular connective tissue, and PLV: perilimbal 
vessels. b) Schematic illustration of assembly of β-galactosidase-loaded PMA capsules via layer-by-layer technique. i) Aminated silica particle template 
is coated with ii) β-galactosidase, followed by sequential deposition of iii) thiol-functionalized PMA (PMASH) and iv) poly(N-vinylpyrrolidone) (PVP) 
via hydrogen bonding. v) Once four bilayers of PMASH/PVP are deposited, the thiol groups of PMASH are oxidized into bridging disulfide linkages. 
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saline with divalent cations and 5.5 × 10−3 m glucose). We used 
an NO-sensitive electrode immersed in β-galactosidase solu-
tion (0.1 mg mL−1) and measured changes in NO concentration 
over time in response to the addition of β-gal-NONOate 
(50 × 10−6 m). β-Galactosidase catalyzes the release of NO by 
hydrolysis of the glycosidic bonds. Upon addition of NO donors 
into the β-galactosidase solution, an increasing production of 
NO was detected, followed by a decline back to the original 
baseline signal (Figure 1a). This reaction generated NO with 
an average half-life (t1/2) of ≈5 min at physiological conditions 
(pH 7.4 and 37 °C), which refers to the time to reach 50% NO 
decay. With the same concentration of enzyme (0.1 mg mL−1 
β-galactosidase) and an increasing amount of added substrates, 
NO can be released in a dose-dependent manner (Figure 1b). 
The concentration of NO generated by β-galactosidase-mediated 
hydrolysis of β-gal-NONOate was derived by correlation with a 
calibration curve (Figure S1, Supporting Information). The 
release of NO followed a 1:2 stoichiometry and exhibited a 
linear relationship. These β-galactosidase (0.1 mg mL−1)/β-gal-
NONOate (50 × 10−6 m) pairs released NO at physiologically 
relevant concentrations required to activate soluble guanylate 
cyclase in the TM to increase outflow facility and decrease ele-
vated IOP in vivo.[8,21,46,47]
Using the same setup, we next investigated the kinetics of NO 
release when enzymes and NO donors were spatially separated 
and encapsulated in polymer capsules and liposomes, respec-
tively. Here, β-galactosidase was adsorbed onto amine-functional-
ized silica particles, followed by the sequential deposition of four 
bilayers of PMASH and PVP. The thiol groups within the polymer 
layers were cross-linked with 2,2′-dithiodipyridine, and disulfide-
stabilized hollow PMA capsules containing β-galactosidase were 
obtained upon dissolution of the silica templates (Scheme 1b). 
To confirm the encapsulation of β-galactosidase, we conjugated 
the enzyme with Alexa Fluor 488 dye. Fluorescence micros-
copy imaging of capsules containing Alexa Fluor 488-labeled 
β-galactosidase showed a homogeneous green corona on the 
capsule membrane (Figure S2, Supporting Information). The 
hollow capsules were intact, non-agglomerated, and preserved 
the spherical shape of the particle templates. The NO donor, 
β-gal-NONOate, was encased within zwitterionic 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes.
Here, an NO-sensitive electrode was immersed and equili-
brated in a suspension of capsules containing β-galactosidase in 
DBG solution (106 capsules µL−1), and we measured NO release 
in response to the addition of β-gal-NONOate-loaded liposomes 
(50 × 10−6 m β-gal-NONOate, 106 liposomes µL−1) within a glass 
vial. This reaction was performed at 37 °C on a hot plate with 
continuous mixing. Upon introduction of liposomes to the cap-
sule suspension, a maximal NO concentration of ≈900 × 10−9 m 
was generated in 30 min, followed by a gradual decay over 6 h to 
the baseline signal (Figure 2a). By spatial separation and encap-
sulation of enzymes and NO donors into polymer capsules and 
liposomes, respectively, the half-life of NO released increased 
30-fold, extending the t1/2 from ≈5 min to ≈2.5 h, which is 
highly beneficial for treatment that requires sustained delivery 
of NO. NO donors were gradually released from lipid vesicles 
over time, freely permeating through the shell of the PMA cap-
sules and were subsequently hydrolyzed by β-galactosidase. 
This led to a staggered generation of NO greater than the deple-
tion of NO in solution. Successful generation of NO indicated 
that core removal did not cause loss of enzyme activity in the 
capsules, as previously reported.[33,34,36]
To demonstrate the ability to control the dose of released 
NO, we spiked varying concentrations of β-gal-NONOate-
loaded liposomes (25 × 10−6 to 75 × 10−6 m β-gal-NONOate, 106 
liposomes µL−1) into the same suspension of capsules containing 
β-galactosidase in DBG solution (106 capsules µL−1). We observed 
a dose-dependent generation of NO (250 × 10−9 to 1250 × 10−9 m, 
which corresponded to the maximal NO concentration generated 
in 30 min) as a function of increasing concentration of β-gal-
NONOate encapsulated inside the liposomes (Figure 2b). These 
data demonstrated that through enzyme biocatalysis, the desired 
amount of NO delivery can be tuned independently via the 
choice of concentration of administered NO donors.
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Figure 1. Nitric oxide (NO) release by β-galactosidase-mediated hydrolysis of β-gal-NONOate. a) Representative dose-response curve of NO generated 
from enzymatic hydrolysis of increasing boluses of β-gal-NONOate (50 × 10−6 m) by β-galactosidase (0.1 mg mL−1) in DBG solution (Dulbecco’s PBS 
with divalent cations and 5.5 × 10−3 m glucose) at 37 °C. NO release was measured using an NO-sensitive probe (ISO-NO Mark II). b) Linear relation-
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To demonstrate a sustained delivery of NO, we repeated the 
enzymatic catalysis over three cycles by removing the hydrolyzed 
substrates and adding fresh β-gal-NONOate-loaded liposomes 
(75 × 10−6 m β-gal-NONOate, 106 liposomes µL−1) into the sus-
pension of capsules containing β-galactosidase in DBG solution 
(106 capsules µL−1). Using methodology used in this work, over 
42 h, the enzyme retained at least 50% of its activity (Figure 2c), 
and this approach allows NO delivery that can be tuned at the 
desired units of time through the rate of liposome administra-
tion. We are now investigating means to extend the lifetime of 
the enzyme and to provide for greater duration of treatment.
To simulate the effects of localized delivery 
of NO in vivo and to evaluate their impact 
on a physiological parameter (conventional 
outflow), we measured outflow facility (Cr) 
in enucleated eyes from C57BL/6 male 
wild-type mice. Outflow facility is the math-
ematical inverse of outflow resistance. This 
study consists of a two-step experimental 
protocol: i) delivery of β-galactosidase-loaded 
capsules (1.5 × 106 capsules) to conventional 
outflow tissues via intracameral injections in 
living mice, and ii) ex vivo delivery of β-gal-
NONOate-loaded liposomes (106 liposomes) 
during perfusion of enucleated eyes 48 h 
after intracameral injections. This approach 
allowed for sufficient recovery time and for 
the capsules to be enmeshed into active fil-
tration regions of the TM prior to adminis-
tration of β-gal-NONOate-loaded liposomes. 
Microparticles delivered into the TM may 
induce IOP elevations in otherwise healthy 
mice.[48,49] However, this response typically 
requires larger particles (e.g., 15 µm[48]) or the 
addition of 10 mg mL−1 hyaluronate solution 
in addition to smaller particles (1–6 µm[49]) 
similar in size to those used in the current 
study. To control for potential IOP elevation, 
sham-treated eyes were injected with other-
wise identical capsules lacking enzyme. The 
use of enucleated eyes allowed for accurate 
measurements of outflow facility in mice 
with the iPerfusion system[50] by eliminating 
pressure-independent outflow, aqueous 
humor inflow, and episcleral venous pres-
sure, which are only present in living mice. 
Previous studies have shown that ex vivo 
eyes remain pharmacologically responsive 
to NO for up to several hours[6] and respond 
to receptor mediated compounds for up to 
24 h.[51]
All experiments used paired eyes, where 
the experimental eye received capsules 
containing β-galactosidase, while the con-
tralateral control eye received empty cap-
sules. Both eyes were enucleated for ex 
vivo mouse eye perfusions, where the per-
fusate consisted of liposomes containing 
β-gal-NONOate (50 × 10−6 m) in DBG solu-
tion, and were pressurized at 8 mmHg to allow the eyes 
to acclimatize to the pressure and temperature environ-
ment. After the acclimatization period, eyes were perfused 
over seven increasing pressure steps, from 6 to 15 mmHg. 
Figure 3a shows a sample flow-pressure plot comparing 
contralateral control and treated eyes, which indicates an 
apparent increasing effect of NO delivery on the flow rate. 
To determine the effect of localized NO delivery on Cr, pres-
sure and flow data for each step were averaged, and a power 
law regression was fit to the data according to Q = Cr(P/Pr)βP, 
where Q is the flow rate, P is the pressure, Pr is the reference 
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Figure 2. Nitric oxide (NO) release from β-galactosidase encapsulated in capsules and β-gal-
NONOate loaded in liposomes. a) Representative NO decay curve from enzymatic hydrolysis 
of β-gal-NONOate from liposomes (50 × 10−6 m, 106 liposomes µL−1) by β-galactosidase encap-
sulated in capsules (106 capsules µL−1) or enzymatic hydrolysis of non-encapsulated β-gal-
NONOate and β-galactosidase in DBG solution at 37 °C. By spatially separating enzymes and 
NO donors into polymer capsules and liposomes, respectively, the half-life of NO released 
increased significantly, extending the t1/2 from ≈5 min to ≈2.5 h. A maximal NO concentra-
tion of ≈900 × 10−9 m was generated in 30 min. b) Maximal NO concentration generated 
in 30 min as a function of increasing loading concentration of β-gal-NONOate encapsulated 
inside the liposomes (25 × 10−6 to 75 × 10−6 m β-gal-NONOate, 106 liposomes µL−1), which 
were added into a suspension of capsules containing β-galactosidase (106 capsules µL−1) in 
DBG solution at 37 °C (n = 3 for each concentration; error bars are SD). c) Sustained release 
of NO from β-galactosidase encapsulated in PMA capsules and β-gal-NONOate loaded in 
liposomes. Representative NO decay curve from enzymatic hydrolysis of β-gal-NONOate from 
liposomes (75 × 10−6 m, 106 liposomes µL−1) by β-galactosidase encapsulated in capsules 
(106 capsules µL−1) in DBG solution at 37 °C is shown. The enzymatic catalysis was repeated 
over three cycles by removing the hydrolyzed substrates and adding fresh β-gal-NONOate-
loaded liposomes into the suspension of capsules containing β-galactosidase. Over 42 h the 
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pressure, Cr is the reference facility at Pr, and β characterizes 
the non-linearity of the data (see the Experimental Section 
for a description of outflow facility analysis). The delivery of 
β-gal-NONOate-loaded liposomes in the presence of capsules 
containing β-galactosidase resulted in an average increase 
in Cr by 84% [23, 177%] (mean [95% CI]) relative to vehicle-
treated contralateral eyes (p = 0.011, n = 7 pairs, weighted 
t-test, average facility values: 6.50x/1.57 nL min−1 mmHg−1 vs 
3.55x/1.38 nL min−1 mmHg−1, Figure 3b; see the Experimental 
Section for a description of statistical reporting).
In the current study, the structural integrity of the 
β-galactosidase-loaded PMA capsules allowed them to be local-
ized to, and enmeshed within, TM likely within the down-
stream juxtacanalicular portion of the TM where the bulk of 
outflow resistance is thought to be generated.[52,53] Provided 
there is a supply of NO donors, NO can be continuously and 
locally released and delivered to the outflow resistance sites 
within the lifetime of the enzymes. A portion of NO donors 
might be cleared through aqueous outflow; however, segmental 
flow will tend to cluster β-gal-NONOate-loaded liposomes and 
β-galactosidase-loaded capsules into the active filtration regions 
of the TM, where their close proximity will minimize the diffu-
sion distance necessary for the substrate to reach the enzyme. 
By coupling an enzyme-prodrug therapy mechanism[54–56] with 
smart biomaterial encapsulation, we localized the delivery of 
NO to the target tissue, and the desired dose of therapeutics 
can be tuned by varying the concentration of externally admin-
istered NO donors within the liposomes—two highly desirable 
features for effective NO-mediated IOP-lowering therapy.
In conclusion, we have developed a platform for delivering 
NO to the targeted outflow resistance sites within the conven-
tional outflow pathway, utilizing the strategy of on-site NO 
release via enzyme biocatalysis to increase outflow facility. 
Our platform will allow future manipulation of NO delivery 
in a dose- and time-dependent manner without concern of off-
target effects, and potentially help compensate for the impaired 
NO-regulatory machinery[57–59] within the conventional outflow 
pathway that contributes toward the pathogenesis of glaucoma. 
The strategy developed is generic and may open new routes to 
the next generation of localized therapeutic delivery.
Experimental Section
In Vivo Intracameral Injections of β-galactosidase-Loaded Capsules: All 
animal experiments were conducted in compliance with the Association 
for Research in Vision and Ophthalmology Statement for the Use of 
Animals in Ophthalmic and Vision Research under UK Home Office 
Project License approval for research at Imperial College London (PPL 
70/7306). Mice were first anesthetized with ketamine (66.6 mg kg−1, 
Fort Dodge Animal Health) and Domitor (medetomidine hydrochloride, 
0.66 mg kg−1, Orion Pharma) via intraperitoneal (IP) injection. Each 
mouse received dilation drops (2.5% w/v phenylephrine hydrochloride 
and 1% w/v tropicamide, Bausch & Lomb) to both eyes to minimize 
potential damage to the iris during injection. This was followed by a 
subcutaneous injection of enrofloxacin antimicrobial (5 mg kg−1, Bayer 
Healthcare). Eyes were kept moist with artificial tears (Vidisic, Bausch 
& Lomb) prior to intracameral injections. For intracameral injections, 
mice were secured in place with the assistance of a head holder (model 
923-B, Kopf Instruments) and placed on a warm-water place mat. Eyes 
were first cannulated with a pulled glass microneedle (100 µm tip) 
Adv. Mater. 2017, 1604932
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Figure 3. Effects of localized delivery of nitric oxide (NO) on conventional outflow facility in eyes obtained from C57BL/6 mice. Paired eyes were injected 
with either capsules containing β-galactosidase (experimental) or empty capsules (control) 48 h prior to ex vivo mouse eye perfusions. Enucleated eyes 
were perfused with β-gal-NONOate-loaded liposomes (50 × 10−6 m) to determine the flow-pressure relationships for paired eyes. a) Representative 
flow-pressure relationship for a given pair of eyes is shown. Solid lines represent the power law fitting of the data set. Shaded regions represent the 
95% confidence bounds on the fitting. Error bars represent the two standard deviations for the flow rate at each pressure step. b) Cello plots showing 
relative difference in outflow facility (Cr) between contralateral eyes perfused with β-gal-NONOate-loaded liposomes (p = 0.011, n = 7, weighted t-test). 
The delivery of β-gal-NONOate-loaded liposomes in the presence of capsules containing β-galactosidase resulted in an average increase in Cr by 84% 
[23, 177%] relative to vehicle-treated contralateral eyes. The shaded regions represent the log-normal distribution that best describes the data, while 
the thick white central lines indicate the geometric means. Error bars represent the 95% confidence intervals on the relative difference in facility. The 
dark shaded regions indicate the 95% confidence intervals on the geometric mean, and the outer thin white lines indicate the range that approximately 
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positioned parallel to the iris and above the limbus, to remove a portion 
of the aqueous humor in the anterior chamber by capillary action. 
Intracameral injections were then carried out with a separate pulled 
glass microneedle filled with 1.5 µL of β-galactosidase-loaded PMA 
capsules (106 capsules µL−1, treated eyes) or empty PMA capsules 
(106 capsules µL−1, control eyes) in UltraPure DNase/RNAse-free dH2O 
(Invitrogen) connected to a 10 µL glass gastight syringe (Hamilton). The 
needle was inserted into the same cannulation site with the assistance 
of a micromanipulator, and 1.5 × 106 PMA capsules were delivered to 
the anterior chamber of the eye. Topical antibiotic ointment (1% w/w 
Fucithalmic, LEO Pharma) was then applied to the eyes followed by 
slow removal of the needle from the eye to reduce reflux. After the 
procedures, the mice were given Antisedan (atipamezole hydrochloride, 
1.5 mg kg−1, Orion Pharma) via IP injections and placed in a heated 
chamber (maintained at 28 °C) to allow for faster recovery from 
anesthesia. The mice were allowed to recover for 48 h post-intracameral 
injections, before they were euthanized by overdose of pentobarbital 
(100 µL, Euthatal, Merial Animal Health) and the eyes were enucleated 
for ex vivo perfusions.
Ex Vivo Delivery of β-gal-NONOate-Loaded Liposomes via Mouse Eye 
Perfusions: Eyes from mice (post-intracameral delivery of PMA capsules) 
were enucleated within 10 min of death by overdose of pentobarbital and 
stored in phosphate buffered saline (PBS) at room temperature until 
perfusion, typically within 15 min. Experiments used paired contralateral 
eyes, which were perfused simultaneously on two identical iPerfusion 
systems[50] under identical experimental conditions. Our cannulation 
method follows previously described techniques.[5,6,60] Briefly, the eye 
was affixed to a support using cyanoacrylate glue and submerged in 
PBS in a thermoregulated bath at 35 °C. A 33-gauge beveled needle 
(Nanofil, World Precision Instruments) was used to cannulate the eye, 
with the tip of the needle positioned in the anterior chamber using a 
micromanipulator. The pressure and flow rate inside the eye were 
measured using a wet–wet differential pressure transducer (PX409, 
Omegadyne) and a thermal flow sensor (SLG64-0075, Sensirion), 
respectively. The enucleated eyes were perfused with β-gal-NONOate-
loaded liposomes in DBG (50 × 10−6 m β-gal-NONOate, 106 liposomes). 
Both treated and control eyes were pressurized from a reservoir at 
8 mmHg for 45 min to allow the eyes to acclimatize to the pressure 
and temperature environment. During this acclimatization period, the 
anterior chamber was filled with liposomes which flowed toward the 
filtration-active regions of the TM, where the β-galactosidase-loaded 
PMA capsules were enmeshed. After the acclimatization period, eyes 
were perfused over seven increasing pressure steps, from 6 to 15 mmHg 
with a motorized reservoir.
Outflow Facility Analysis: Conventional outflow facility was defined as 
previously described by Sherwood et al.[50] Briefly, for each eye, the last 
4 min of steady state pressure and flow data for each step were averaged, 
and a power law regression was fit to the data according to Q = Cr(P/Pr)β 
P, where Q is the flow rate, P is the pressure, Pr is the reference pressure, 
Cr is the reference facility at Pr, and β characterizes the non-linearity of the 
data. This model is used rather than the more common linear model, as 
it was shown that neither the assumption of pressure-independent facility 
nor of a finite flow rate at zero pressure are valid in enucleated mouse 
eyes.[50] We therefore consider the facility at a “physiological” pressure 
drop across the outflow pathway in vivo, IOP-EVP = Pr = 8 mmHg, 
and Cr acts as an indicator of the physiological facility. It should be 
noted that although Cr represents the total outflow facility, which 
comprises trabecular facility and any pressure dependent components of 
unconventional outflow, the latter are relatively diminutive and hence Cr 
is a good representation of the conventional outflow facility. Additionally, 
based upon population studies, the distribution of outflow facility data 
is more accurately represented by a lognormal distribution; therefore, 
outflow facility values are expressed as Cx/ME95, where ME95 is the 95% 
margin of error, such that the 95% confidence intervals can be calculated 
as [C/ME95, C×ME95]. In order to determine whether the observed 
treatment effect was statistically significant, a weighted paired t-test was 
used on the log-transformed Cr values according to Sherwood et al.[50]
Detailed methods are available in the Supporting Information.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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